当代简易风险评分预测经皮冠状动脉介入治疗后对比剂相关急性肾损伤:基于观察性登记研究的推导与验证
该研究基于单一大三级中心2012年1月1日至2020年12月31日连续PCI患者,推导队列2012-2017年14616例、验证队列2018-2020年5606例,仅排除慢性透析患者。主要终点为按急性肾损伤网络(AKIN)定义的对比剂相关急性肾损伤。多因素logistic回归筛选独立预测因子,Model 1仅术前变量、Model 2加术中变量,按效应估计赋权重整数评分。推导队列四组风险评分从低到高对比剂相关急性肾损伤发生率Model 1为2.3%至34.9%、Model 2为2.0%至38.8%;区分度C统计量推导队列Model 1 0.72、Model 2 0.74,验证队列Model 1 0.84、Model 2 0.86。发生对比剂相关急性肾损伤者1年死亡风险显著升高(10.2% vs 2.5%;调整HR 1.76,95%CI 1.31-2.36;p=0.0002),主要归因于30天死亡过多。
要点
- 对比剂相关急性肾损伤总体发生率为4.3%(860例),推导队列按四组风险评分从低到高发生率Model 1为2.3%至34.9%、Model 2为2.0%至38.8%。
- Model 1独立预测因子为临床表现、估算肾小球滤过率、左心室射血分数、糖尿病、血红蛋白、基础血糖、充血性心力衰竭和年龄。
- Model 2额外纳入对比剂用量、围术期出血、术后无复流或慢血流、复杂PCI解剖。
- 区分度C统计量:推导队列Model 1 0.72、Model 2 0.74;验证队列Model 1 0.84、Model 2 0.86。
- 发生对比剂相关急性肾损伤者1年死亡风险升高(10.2% vs 2.5%;调整HR 1.76,95%CI 1.31-2.36;p=0.0002),主要来自30天死亡过多。
适用人群与场景
- 2012年1月1日至2020年12月31日在单一大三级中心连续接受PCI、术前及术后48小时内均有肌酐测量的患者;仅排除慢性透析患者。
- 排除无配对肌酐测量、慢性透析及多次手术者后,推导队列14616例(平均年龄66.2岁,女性29.2%),验证队列5606例(平均年龄67.0岁,女性26.4%)。
诊断标准与关键阈值
- 对比剂相关急性肾损伤按急性肾损伤网络(Acute Kidney Injury Network)标准定义。
- 风险评分基于多因素logistic回归各独立变量效应估计赋权重整数分,Model 1仅用术前变量,Model 2加术中变量。
研究设计与关键结果
- 研究类型为观察性登记研究,推导队列2012-2017年14616例、验证队列2018-2020年5606例,主要终点对比剂相关急性肾损伤发生860例(4.3%)。
- Model 1独立预测因子:临床表现、估算肾小球滤过率、左心室射血分数、糖尿病、血红蛋白、基础血糖、充血性心力衰竭、年龄;Model 2另加对比剂用量、围术期出血、术后无复流或慢血流、复杂PCI解剖。
- 推导队列四组风险评分从低到高对比剂相关急性肾损伤发生率:Model 1 2.3%至34.9%,Model 2 2.0%至38.8%。
- 区分度C统计量:推导队列Model 1 0.72、Model 2 0.74;验证队列Model 1 0.84、Model 2 0.86;加入术中变量仅轻度改善区分度。
- 发生对比剂相关急性肾损伤者1年死亡风险显著升高(10.2% vs 2.5%;调整HR 1.76,95%CI 1.31-2.36;p=0.0002),主要归因于30天死亡过多。
证据类型、等级与局限
- 证据类型:观察性登记研究(推导与验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对接受PCI的患者,可用术前即可获得的变量(Model 1)计算简易风险评分来区分对比剂相关急性肾损伤风险;加入术中变量(Model 2)仅轻度提高区分度(推导队列C统计量0.72 vs 0.74)。
- 发生对比剂相关急性肾损伤与后续死亡强相关(1年死亡10.2% vs 2.5%;调整HR 1.76,95%CI 1.31-2.36;p=0.0002),主要来自30天死亡过多。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Contrast-associated acute kidney injury can occur after percutaneous coronary intervention (PCI). Prediction of the contrast-associated acute kidney injury risk is important for a tailored prevention and mitigation strategy. We sought to develop a simple risk score to estimate contrast-associated acute kidney injury risk based on a large contemporary PCI cohort.
METHODS: Consecutive patients undergoing PCI at a large tertiary care centre between Jan 1, 2012, and Dec 31, 2020, with available creatinine measurements both before and within 48 h after the procedure, were included; only patients on chronic dialysis were excluded. Patients treated between 2012 and 2017 comprised the derivation cohort and those treated between 2018 and 2020 formed the validation cohort. The primary endpoint was contrast-associated acute kidney injury, defined according to the Acute Kidney Injury Network. Independent predictors of contrast-associated acute kidney injury were derived from multivariate logistic regression analysis. Model 1 included only pre-procedural variables, whereas Model 2 also included procedural variables. A weighted integer score based on the effect estimate of each independent variable was used to calculate the final risk score for each patient. The impact of contrast-associated acute kidney injury on 1-year deaths was also evaluated.
FINDINGS: 32 378 PCI procedures were performed and screened for inclusion in the present analysis. After the exclusion of patients without paired creatinine measurements, patients on chronic dialysis, and multiple procedures, 14 616 patients were included in the derivation cohort (mean age 66·2 years, 29·2% female) and 5606 were included in the validation cohort (mean age 67·0 years, 26·4% female). Contrast-associated acute kidney injury occurred in 860 (4·3%) patients. Independent predictors of contrast-associated acute kidney injury included in Model 1 were: clinical presentation, estimated glomerular filtration rate, left ventricular ejection fraction, diabetes, haemoglobin, basal glucose, congestive heart failure, and age. Additional independent predictors in Model 2 were: contrast volume, peri-procedural bleeding, no flow or slow flow post procedure, and complex PCI anatomy. The occurrence of contrast-associated acute kidney injury in the derivation cohort increased gradually from the lowest to the highest of the four risk score groups in both models (2·3% to 34·9% in Model 1, and 2·0% to 38·8% in Model 2). Inclusion of procedural variables in the model only slightly improved the discrimination of the risk score (C-statistic in the derivation cohort: 0·72 for Model 1 and 0·74 for model 2; in the validation cohort: 0·84 for Model 1 and 0·86 for Model 2). The risk of 1-year deaths significantly increased in patients with contrast-associated acute kidney injury (10·2% vs 2·5%; adjusted hazard ratio 1·76, 95% CI 1·31-2·36; p=0·0002), which was mainly due to excess 30-day deaths.
INTERPRETATION: A contemporary simple risk score based on readily available variables from patients undergoing PCI can accurately discriminate the risk of contrast-associated acute kidney injury, the occurrence of which is strongly associated with subsequent death.
参考来源
- Mehran R, Owen R, Chiarito M, et al. A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet. 2021. PMID: 34793743. doi:10.1016/S0140-6736(21)02326-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。